NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1,443 | $4,595 | $20,054 | $27,605 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $6 | $7 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,859 | $2,283 | $5,734 | $5,109 |
| Total Curr. Assets | $3,302 | $6,884 | $25,795 | $32,714 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $349 | $431 | $21 | $15 |
| Total NC Assets | $349 | $431 | $21 | $15 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $3,651 | $7,315 | $25,816 | $32,729 |
| Liabilities | – | – | – | – |
| Payables | $4,130 | $4,632 | $2,076 | $3,687 |
| Short-Term Debt | $1,566 | $9,161 | $7,703 | $518 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $16,167 | $5,255 | $5,806 | $7,718 |
| Total Curr. Liab. | $21,863 | $19,048 | $15,585 | $11,923 |
| LT Debt | $5,011 | $0 | $2,822 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $5,011 | $0 | $2,822 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $26,874 | $19,048 | $18,407 | $11,923 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $3 | $0 | $0 |
| Common Stock | $15 | $84 | $67 | $59 |
| Retained Earnings | -$278,273 | -$253,147 | -$222,997 | -$183,243 |
| AOCI | $0 | -$3 | $0 | $0 |
| Other Equity | $255,035 | $241,330 | $230,339 | $203,990 |
| Total Equity | -$23,223 | -$11,733 | $7,409 | $20,806 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $3,651 | $7,315 | $25,816 | $32,729 |
| Net Debt | $5,134 | $4,566 | -$9,529 | -$27,087 |